EP4304605A1 - Aliment et procédés de lutte contre les infestations par les tiques chez un mammifère - Google Patents

Aliment et procédés de lutte contre les infestations par les tiques chez un mammifère

Info

Publication number
EP4304605A1
EP4304605A1 EP22768046.9A EP22768046A EP4304605A1 EP 4304605 A1 EP4304605 A1 EP 4304605A1 EP 22768046 A EP22768046 A EP 22768046A EP 4304605 A1 EP4304605 A1 EP 4304605A1
Authority
EP
European Patent Office
Prior art keywords
spinosyn
mammal
days
group
feed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22768046.9A
Other languages
German (de)
English (en)
Other versions
EP4304605A4 (fr
Inventor
Robin S. READNOUR
Kevin E. WILLARD
Joseph R. Winkle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
In the Bowl Animal Health Inc
Original Assignee
In the Bowl Animal Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by In the Bowl Animal Health Inc filed Critical In the Bowl Animal Health Inc
Publication of EP4304605A1 publication Critical patent/EP4304605A1/fr
Publication of EP4304605A4 publication Critical patent/EP4304605A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/22—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom rings with more than six members
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P17/00—Pest repellants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P7/00—Arthropodicides
    • A01P7/02—Acaricides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the teachings of this disclosure generally relate to a spinosyn, a feed that includes the spinosyn and a method of administering the spinosyn to control tick infestations in mammals.
  • Ticks are vectors of a number of different pathogenic agents in mammals. Examples of diseases which are caused by ticks include borreliosis (Lyme disease caused by Borrelia burgdorferi), babesiosis (or piroplasmosis caused by Babesia microti) and rickettsiosis (Rocky Mountain spotted fever). Ticks also release toxins, which can cause inflammation or paralysis in the host.
  • Tick infestations of wild animals such as deer, elk, caribou, moose, etc.
  • domesticated animals e.g., cattle, cats and dogs
  • Farm animals are also susceptible to various tick infestations, for example, the tick genus Rhipicephalus, especially those of the species microplus (cattle tick), decoloratus and armulatus. Ticks such as Rhipicephalus microplus are particularly difficult to control because they live in pastures where farm animals graze.
  • Rhipicephalus spp. and other tick genera may infest buffalo, horses, donkeys, goats, sheep, deer, pigs, cats and dogs.
  • a heavy tick burden on mammals can decrease production and damage hides as well as transmit diseases such as babesiosis (“cattle fever”) and anaplasmosis caused by protozoan parasites.
  • ticks In addition to farm animals, ticks also spread disease to companion animals and humans, including, for example, Lyme disease, ascending paralysis and Rocky Mountain spotted fever.
  • Treatments currently available for controlling tick infestations achieve varying degrees of success. Many treatments involve chemicals applied to indoor and outdoor surfaces, as well as to the animal.
  • the chemicals used include a variety of carbamates, organophosphates, certain macrocyclic lactones, fiproles, pyrethrins and pyrethroids. These compounds often have toxic side effects that are a problem for both the animal and animal owners. In addition, there is evidence that the use of these chemicals may be ineffective due to acaricide resistance and treatment deficiencies.
  • Topical treatments are a well-known method for controlling tick infestations. While there are numerous ways to deliver these therapeutic agents to the coats and skins of mammals, many of these methods are either ineffective and/or present safety risks to the mammal or user during or after the dispensing activity. More particularly, because a physical connection must be achieved between the applicator tip and the drug delivery device when the applicator tip is installed thereon, there is inherently a risk that the connection will be inadequate, thereby permitting some of the therapeutic agent to leak out of the device and into physical contact with the user.
  • spinosyns such as spinosad
  • spinosyns can provide improved control over tick infestations when orally administered in smaller, more frequent/chronic doses.
  • spinosyns were generally considered ineffective for tick control in pets, or more generally, in mammals because the doses were administered on a monthly basis and the amount of spinosyn in the animal’s blood drops too quickly to control tick infestations.
  • the method and composition taught herein have the further advantage of encouraging compliance because the smaller doses of a spinosyn can be incorporated into a daily feed that, at least in the case of companion animals, would be given to the companion animal in any event, making it less likely that owners will forget or neglect to administer the treatment.
  • this disclosure provides a method for prolonged control of ticks in a safer and more effective manner than that achieved with previously known treatments.
  • spinosyn is discussed below as being combined with feed. However, it is also contemplated that the spinosyn may be administered by itself or in a dosage form other than feed, such as a chew, tablet, liquid, gel or other suitable form for oral administration.
  • Spinosyns are naturally derived fermentation products. They are macrolides produced by cultivation of Saccharopolyspora spinosa. The fermentation of S. spinosa produces many factors, including spinosyn A and spinosyn D (also called A83543A and A8354D). Spinosyn A and spinosyn D are the two spinosyns that are most active as insecticides. A product comprised mainly of these two spinosyns is available commercially under the generic name “spinosad”. The major spinosyn factor, spinosyn A, is particularly known to have an excellent human and mammal safety and toxicological profile.
  • Each spinosyn has a 12-membered macrocyclic ring that is part of an unusual tetracyclic ring system to which two different sugars are attached, the amino-sugar forosamine and the neutral sugar 2N,3N,4N-(tri-O-methyl)rhamnose. This unique structure sets the spinosyns apart from other macrocyclic compounds.
  • Spinosyn A was the first spinosyn isolated and identified from the fermentation broth of S. spinosa. Subsequent examination of the fermentation broth revealed that 8. spinosa produced a number of spinosyns that have been called spinosyns A to J (A83543A to J). The primary components are spinosyns A and D. Additional spinosyns, lettered from K to W, have been identified from mutant strains of 8. spinosa.
  • the various spinosyns are characterized by differences in the substitution patterns on the amino group of the forosamine, at selected sites on the tetracyclic ring system and on the 2N,3N,4N-(tri-O- methyl)rhamnose group.
  • Boeck et al. described spinosyns A-H and J (which they called A83543 factors A, B, C, D, E, F, G, H and J), and salts thereof, in U.S. Pat. Nos. 5,362,634 (issued Nov. 8, 1994); 5,496,932 (issued March 5, 1996); and 5,571,901 (issued Nov. 5, 1996).
  • Mynderse et al. described spinosyns L-N (which they called A83543 factors L, M and N), their N- demethyl derivatives, and salts thereof, in U.S. Pat. No. 5,202,242 (issued Apr. 13, 1993); and Turner et al.
  • spinosyns Q-T which they called A83543 factors Q, R, S and T
  • their N-demethyl derivatives and salts thereof
  • U.S. Pat. Nos. 5,591,606 issued Jan. 7, 1997) and 5,631,155 (issued May 29, 1997).
  • Spinosyns K, O, P, U, V, W and Y are described, for example, by Carl V. DeAmicis, James E. Dripps, Chris J. Hatton and Laura I. Karr in American Chemical Society's Symposium Series: Phytochemicals for Pest Control, Chapter 11, “Physical and Biological Properties of Spinosyns: Novel Macrolide Pest-Control Agents from Fermentation”, pages 146-154 (1997).
  • the spinosyns can react to form salts that are also useful in the methods and formulations of this disclosure.
  • the salts are prepared using standard procedures for salt preparation. For example, spinosyn A can be neutralized with an appropriate add to form an add addition salt.
  • the acid addition salts of spinosyns are particularly useful.
  • Suitable acid addition salts include salts formed by reaction with either an organic or inorganic acid such as, for example, sulfuric, hydrochloric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, cholic, pamoic, mucic, glutamic, camphoric, glutaric, glycolic, phthalic, tartaric, formic, lauric, stearic, salicylic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic and like acids.
  • an organic or inorganic acid such as, for example, sulfuric, hydrochloric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, cholic, pamoic, mucic, glutamic, camphoric, glutaric, glycolic, phthalic, tartaric, formic, lauric, stearic, salicylic, methanesulfonic,
  • spikenosyn refers to an individual spinosyn factor (spinosyn A, B, C, D, E, F, G, H, J, K, L, M, N, O, P, Q, R, S, T, U, V, W or Y), an N- demethyl derivative of an individual spinosyn factor, a chemically modified spinosyn such as spinetoram, a salt of any of the aforementioned, a metabolite of any of the aforementioned, a physiologically acceptable derivative thereof, or a combination thereof.
  • Spinosyns also provide advantages because they are very effective against ticks with post-treatment residual protection, when the dosages described herein are used according to the method disclosed herein. Furthermore, spinosyns have no acaricidal crossresistance to existing compounds. Thus, they are especially useful against tick populations on mammals that have existing levels of resistance to currently used acaricidal products. Spinosyns, therefore, can be used in integrated pest management (IPM) programs to extend the life line of commonly used products where resistance is not well developed or has not yet developed.
  • IPM integrated pest management
  • Systemic efficacy e.g., ingestion of blood containing spinosyns by ticks
  • the advantages of oral systemic treatments and killing of ticks from their ingestion of blood, compared to topical applications and contact killing, include: a) reduced exposure to the human applicator and children and objects in the mammal’s environment (e.g., flooring, carpets, furniture); b) no worry about loss from exposure of the mammal to water (lakes, streams, bathing, etc.) or from loss due to rubbing; c) no concern about UV exposure and degradation; d) no problems with oxidation from oils on skin, etc.; and e) assurance that the entire dose is administered (compared to a topical application where some of the dose may drip off, rub off and/or remain in the dispensing tube immediately after treatment).
  • the formulations, or feeds, and methods of this disclosure may further include, in combination with the spinosyn, one or more other active substances having therapeutic efficacy.
  • active substances include agents efficacious against ticks.
  • Active substances may include, for example, isoxazolines, certain macrocyclic lactones, tick specific chitin synthesis inhibitors, pyridines and pyrazoles or fiproles.
  • the methods of this disclosure are carried out by administering the spinosyn to the mammal in small, frequent doses.
  • the spinosyn administration may be carried out using a daily feed.
  • feeds in the broad categories of dry feeds, semi-moist feeds, wet feeds, canned-retorted feeds, fresh refrigerated feeds, and supplemental feeds including treats, snacks and other supplemental feeds may be adapted for use with this disclosure.
  • the mammal receives a maintenance quantity of spinosyn by consuming the feed product on a weekly, semi-weekly or daily basis.
  • spinosyn By incorporating smaller doses of spinosyn into an animal feed composition and administering it at an effective frequency (most likely daily), the blood level of spinosyn rises over time until it reaches an optimal steady state where it can be maintained by a daily or substantially daily dosage.
  • spinosyn is orally administered in larger doses at lower frequency, e.g., a single treatment of a large dose that is administered via “treat” once in a 30-day period, the level of spinosyn in the blood spikes at the time of the dose and then declines until the next dose is administered.
  • the administration of a large dose at low frequency means that the animal must consume more spinosyn in each dose so that the blood level of spinosyn does not fall below the necessary level for effective protection before the next dose. Because of the rapid and precipitous decline in the blood level of spinosyn, it has not been possible to maintain a sufficient blood level to control tick infestations using a monthly dosing strategy.
  • controlling a tick infestation refers to preventing, treating, minimizing or eliminating an infestation by ticks on a mammal.
  • tick refers to any member of the order Ixodida.
  • the term “tick” includes the egg, larval, nymph, and adult stages of development. More particularly, the term tick includes ticks of the families Ixodidae and Argasidae. More particularly, the term “tick” includes species of the genera Ajricaniella, Amblyomma, Anomalohimalaya, Bothriocroton, Dermacentor, Haemaphysalis, Hyalomma, Ixodes, Margaropus, Nosomma, Rhipicentor, Rhipicephalus, Antricola, Argos, Nothoaspis, Omithodoros, and Otobius.
  • mammal refers to any member of the class Mammalia. In particular, it may refer to wild mammals, such as wolves, coyotes, jackals, deer, elk, moose, reindeer, and the like. It may also refer to farm animals, such as cows, sheep, pigs, bison, horses and the like. It may also refer to companion animals. It may also refer to humans.
  • the term “companion animal” refers to any domestic animal that may be kept as a pet. This includes, but is not limited to, horses, dogs, wolves, coyotes, cats, hamsters, gerbils, mice, guinea pigs, ferrets, rabbits, etc.
  • Canine refers to any member of the genus Canis, which includes such species as wolves, dogs, coyotes and jackals.
  • feline refers to any member of the subfamily Felidae, which includes such species as the domestic cat, bobcats, wildcats, ocelots, members of the genus lynx, Pallas’s cat and cougars.
  • a “feed” is an animal feed, snack, treat or other supplemental feed that may be administered daily or substantially daily.
  • feed e.g., kibble and treats or chews
  • the mammal’s meals and snacks may be varied from time to time while still conveniently administering a daily dose of spinosyn.
  • chew refers to a treat that has flavor and aromatic properties that are appealing to a canine, but typically has no nutritional value.
  • a “feed” and/or a “chew” may be used interchangeably.
  • the term “effective time”, also referred to herein as “effective duration”, for the purposes of this disclosure includes at least the duration of feed administration needed to bring the level of spinosyn in the mammal’s blood to a sufficiently high level for controlling ticks, i.e., a “therapeutically effective” level.
  • the effective time may be as little as three days. In other instances, the effective time may be seven days or fifteen days or longer. As discussed below, the effective time will vary based on how frequently the feed or spinosyn is administered.
  • the “effective time” will vary as a function of the frequency at which the feed is administered.
  • the term “effective frequency” as used herein means the number of feedings over a given time that produce a therapeutically effective concentration of spinosyn in the mammal’s blood. In all events, the term “effective frequency” as used herein contemplates multiple feedings including the spinosyn per month.
  • the feed may be administered in a range of frequencies. For example, the spinosyn may be administered at a frequency of daily, every other day, every third day, once per week or even at inconsistent time intervals.
  • the effective frequency may affect the duration required to obtain a therapeutically effective level of spinosyn in the mammal’s blood.
  • the duration of feed administration required to achieve a therapeutically effective level of spinosyn in the mammal’s blood, and thus the “effective time”, would be comparatively less than if the mammal were being fed the feed composition only once or twice per week.
  • the effective frequency is influenced by the amount of the daily dose in mg/kg of body weight of the mammal. Particularly, at slightly higher daily doses, e.g., greater than 1.0 mg/kg, missed doses have less of an impact on efficacy.
  • the effective frequency is influenced by the duration of treatment.
  • the animal feed may need to be administered at a greater frequency than would be necessary if it were being administered after a longer period of use, i.e., once a therapeutically effective level is obtained.
  • substantially daily means a sufficiently regular basis such that the spinosyn concentration in the mammal’s blood rises to and remains at a therapeutically effective level.
  • the disclosed feed composition can preferably be fed to a mammal every day indefinitely. However, as a practical matter, there are many reasons days may be missed or skipped periodically. For example, the mammal may be ill or the owner may run out of the feed composition. The disclosed method is robust enough that the mammal will still be protected from ticks to some extent even with occasional interruptions in doses of spinosyn.
  • the term “substantially daily” includes at least 10 days per month, more preferably at least 15 days per month, still more preferably at least 20 days per month. All of these feeding frequencies, whether they be, e.g., three times per week, every other day or daily, fit under the umbrella of “substantially daily” as used in this disclosure, provided that they promote the spinosyn reaching and maintaining a therapeutically effective level of the spinosyn in the mammal’s blood.
  • the term “therapeutically effective” means that the dose of a spinosyn in the feed or concentration of a spinosyn in the blood is sufficient to control the tick infestation better than if no drug were present.
  • the spinosyn may be present in, e.g., the feed, or the mammal’s blood on its own or with one or more additional active substances. Preferably it controls the tick infestation at around at least 50% better than if no drug were present, and more preferably it controls the tick infestation at about at least 90% better than if no drug were present.
  • an effective or therapeutically effective amount of a spinosyn is administered orally to the mammal.
  • the term “effective amount” or “therapeutically effective amount” refers to the amount needed to control the tick infestation. As those in the art will understand, this amount will vary depending upon a number of factors. These factors include, for example, the type of mammal being treated, its body weight and general physical condition.
  • concentrations of spinosyn in terms of feeds such as kibble it also contemplates administration using other dosage forms, such as treats or chews. It is also contemplated that the spinosyn may be administered by itself or in a tablet, liquid, gel or other suitable form for oral administration.
  • concentration of spinosyn will vary according to the particular dosage form. For example, where the dosage form is a treat or chew, the concentration of spinosyn in the treat or chew will be greater than, e.g., the concentration of spinosyn in kibble.
  • an effective amount refers to a dose of from about 0.625 to about 10 mg of the spinosyn/kg of body weight of the mammal. More preferably, an effective amount refers to a dose of from about 1 to about 4.5 mg of the spinosyn/kg of body weight of the mammal. More commonly, the effective amount is from about 1 to about 3.75 mg/kg of body weight of the mammal.
  • Animal feeds will typically contain from about 0.005 to about 2 percent of spinosyn (by weight) in the feed, preferably between about 0.01 to about 0.5 percent of spinosyn (by weight) in the feed, most preferably between about 0.03 to about 0.2 percent of spinosyn (by weight) in the feed.
  • this disclosure relates to a method of controlling a tick infestation in a mammal by administering a systemically active oral composition including spinosyn, or a physiologically acceptable derivative or salt thereof, and animal feed at least once per week, more preferably three times per week, most preferably substantially daily.
  • this disclosure relates to a systemically active oral composition that includes a spinosyn and animal feed.
  • This disclosure also relates to the use of a spinosyn for the manufacture of an animal feed for controlling a tick infestation on a mammal.
  • This disclosure also relates to a method of controlling a tick infestation on a mammal for a prolonged time, comprising orally administering daily or substantially daily doses of an effective amount of a spinosyn to the mammal in, e.g., a feed.
  • a daily feed is a feed which is intended to be administered daily, however which may be administered less frequently than daily, as described herein.
  • This method is especially useful for controlling ticks on a mammal for a prolonged time comprising orally administering substantially daily doses of an effective amount of a spinosyn to the mammal.
  • An aspect of this disclosure is the oral administration of an amount of spinosyn that is, in and of itself, ineffective or sub-optimal for controlling a tick infestation in a mammal in a single dose, e.g., once every month, but over time with repeated administrations, as described herein, results in efficacious control of tick infestations.
  • Ineffective or sub-optimal means that a single dosing, as well as several dosings, results in less than a 50% reduction in the tick infestation, including no, or substantially no, reduction, as compared to no drug administration at all. This reflects the chronic, rather than acute, administration aspect disclosed herein.
  • Embodiment 1 A method of controlling a tick infestation in a mammal in need thereof, comprising orally administering to said mammal an effective amount of a spinosyn for an effective time at a frequency of at least 4 times per month.
  • Embodiment 2 The method of embodiment 1, wherein said mammal is selected from the group consisting of a wild animal, a farm animal, a companion animal and a canine.
  • Embodiment 3 The method of embodiments 1 or 2, wherein said spinosyn is spinosad.
  • Embodiment 4 The method of any of embodiments 1-3, wherein said is provided in a feed selected from the group consisting of dry food and a wet food.
  • Embodiment 5 The method of any of embodiments 1-3, wherein said spinosyn is present in an amount of between about 0.005% to 2% of a feed.
  • Embodiment 6 The method of any of embodiments 1-5, wherein said spinosyn is administered to said mammal in an amount of between about 0.625 mg/kg and 10 mg/kg of weight of said mammal.
  • Embodiment 7 The method of any of embodiments 1-6, wherein said frequency is selected from the group consisting of at least 3 times per week, substantially daily and daily.
  • Embodiment 8 The method of any of embodiments 1-7, wherein said effective time is selected from the group consisting of at least one week and at least two weeks.
  • Embodiment 9 The method of any of embodiments 1-8, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood within a time period selected from the group consisting of one week of the first administration of said spinosyn and two days of the first administration of said spinosyn.
  • Embodiment 10 The method of any of embodiments 1-9, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood for a time period selected from the group consisting of at least 30 days, at least 60 days, at least 90 days, at least 180 days and at least 365 days.
  • Embodiment 11 The method of any of embodiments 1-10, wherein said administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 6000 ng/mL in said mammal’s blood for a period of time selected from the group consisting of at least 30 days and at least 365 days.
  • Embodiment 12 The method of any of embodiments 1-11, wherein said spinosyn is administered for a number of days selected from the group consisting of at least 15 out of 30 days and at least 20 out of 30 days.
  • Embodiment 13 The method of any of embodiments 1-12, wherein said spinosyn is provided as a component of a feed that comprises one or more other active substances.
  • Embodiment 14 The method of any of embodiments 1-13, further comprising discontinuing the administration of spinosyn for a period of time selected from the group consisting of at least 3 days and at least 7 days, wherein the mammal’s blood concentration of spinosyn is maintained at a therapeutically effective level during the period of time.
  • Embodiment 15 The method of embodiment 14, further comprising resuming the administration spinosyn after the discontinuing of the administration of spinosyn and thereby continuing to maintain the mammal’s blood concentration of spinosyn at the therapeutically effective level.
  • Embodiment 16 The method of embodiment 1, wherein the spinosyn is a component of a chew.
  • Embodiment 17 The method of embodiment 16, wherein the oral administration includes a feeding frequency selected from the group consisting of: at least 3 times per week, substantially daily and daily.
  • Embodiment 18 A spinosyn for use in controlling ticks on a mammal in need thereof, said spinosyn being administered in an effective amount to said mammal for an effective time at a frequency of at least four times per month.
  • Embodiment 19 The spinosyn of embodiment 18, wherein said mammal is selected from the group consisting of a wild animal, a farm animal, a companion animal and a canine.
  • Embodiment 20 The spinosyn of any of embodiments 18-19, wherein said spinosyn is spinosad.
  • Embodiment 21 The spinosyn of any of embodiments 18-20, wherein said wherein said spinosyn is provided in a feed selected from the group consisting of dry food and wet food.
  • Embodiment 22 The spinosyn of any of embodiments 18-21, wherein said spinosyn is present in an amount of between about 0.005% to 2% of feed.
  • Embodiment 23 The spinosyn of any of embodiments 18-22, wherein said spinosyn is administered to said mammal in an amount of between about 0.625 mg/kg and 10 mg/kg of weight of said mammal.
  • Embodiment 24 The spinosyn of any of embodiments 18-23, wherein said administering includes a feeding frequency selected from the group consisting of at least 3 times per week, substantially daily and daily.
  • Embodiment 25 The spinosyn of any of embodiments 18-24, wherein said effective time is selected from the group consisting of at least one week and at least two weeks.
  • Embodiment 26 The spinosyn of any of embodiments 18-25, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood within a period of time selected from the group consisting of one week of the first administration of said spinosyn and two days of the first administration of said spinosyn.
  • Embodiment 27 The spinosyn of any of embodiments 18-26, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood for a period of time selected from the group consisting of at least 30 days, at least 60 days, at least 90 days, at least 180 days and at least 365 days.
  • Embodiment 28 The spinosyn of any of embodiments 18-27, wherein said administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 6000 ng/mL in said mammal’s blood for a period of time selected from the group consisting of at least 30 days and at least 365 days.
  • Embodiment 29 The spinosyn of any of embodiments 18-28, wherein said feed is administered for a number of days out of 30 selected from the group consisting of at least 15 days and at least 20 days.
  • Embodiment 30 The spinosyn of any of embodiments 18-29, wherein the spinosyn is a component of a feed that comprises one or more additional active substances.
  • Embodiment 31 The spinosyn of any of embodiments 18-30, further comprising discontinuing the administration of spinosyn for a period of time selected from the group consisting of at least 3 days and at least 7 days, wherein the mammal’s blood concentration of spinosyn is maintained at a therapeutically effective level.
  • Embodiment 32 The spinosyn of embodiment 31, further comprising resuming the administration of spinosyn after the discontinuing of the administration of spinosyn and thereby maintaining the mammal’s blood concentration of spinosyn at the therapeutically effective level.
  • Embodiment 33 The spinosyn of embodiments 18-32, wherein the spinosyn is a component of a chew.
  • Embodiment 34 The spinosyn of embodiment 33, wherein the administration includes a feeding frequency selected from the group consisting of: at least 3 times per week, substantially daily and daily.
  • Embodiment 35 A feed or chew for controlling ticks in a mammal, comprising an effective amount of a spinosyn to control a tick infestation when administered for an effective time at a frequency of at least four times per month.
  • Embodiment 36 The feed or chew of embodiment 35, wherein said mammal is selected from the group consisting of a wild animal, a farm animal, a companion animal and a canine.
  • Embodiment 37 The feed or chew of any of embodiments 35-36, wherein said spinosyn is spinosad.
  • Embodiment 38 The feed or chew of any of embodiments 35-37, wherein said feed or chew is a feed selected from the group consisting of a dry food and a wet food.
  • Embodiment 39 The feed or chew of any of embodiments 35-38, wherein said spinosyn is present in an amount of between about 0.005% to 2% of a feed.
  • Embodiment 40 The feed or chew of any of embodiments 35-39, wherein said spinosyn is administered to said mammal in an amount of between about 0.625 mg/kg and 10 mg/kg of weight of said mammal.
  • Embodiment 41 The feed or chew of any of embodiments 35-40, wherein said administration includes a feeding frequency selected from the group consisting of at least 3 times per week, substantially daily and daily.
  • Embodiment 42 The feed or chew of any of embodiments 35-41, wherein said effective time comprises administering the feed or chew for a period of time selected from the group consisting of at least one week and at least two weeks.
  • Embodiment 43 The feed or chew of any of embodiments 35-42, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood within a time period selected from the group consisting of one week of the first administration of said feed or chew and two days of the first administration of said feed or chew.
  • Embodiment 44 The feed or chew of any of embodiments 35-43, wherein said administration provides a therapeutically effective level of spinosyn in said mammal’s blood for a time period selected from the group consisting of at least 30 days, at least 60 days, at least 90 days, at least 180 days and at least 365 days.
  • Embodiment 45 The feed or chew of any of embodiments 35-44, wherein said administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 6000 ng/mL in said mammal’s blood for a period of time selected from the group consisting of at least 30 days and at least 365 days.
  • Embodiment 46 The feed or chew of any of embodiments 35-45, wherein said feed or chew is administered for a number of days out of 30 selected from the group consisting of at least 15 days and at least 20 days.
  • Embodiment 47 The feed or chew of any of embodiments 35-46, wherein said feed or chew comprises one or more other active substances.
  • Embodiment 48 The feed or chew of any of embodiments 35-47, further comprising discontinuing the administration of the feed or chew for a period of time selected from the group consisting of at least 3 days and at least 7 days, wherein the mammal’s blood concentration of spinosyn is maintained at a therapeutically effective level.
  • Embodiment 49 The feed or chew of embodiment 48, further comprising resuming the administration of feed or chew after the discontinuing of the administration of feed or chew and thereby maintaining the mammal’s blood concentration of spinosyn at the therapeutically effective level.
  • administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 6000 ng/mL in said mammal’s blood for at least 30 days. More preferably, administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 2500 ng/mL in said mammal’s blood for at least 30 days.
  • administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 2000 ng/mL in said mammal’s blood for at least 30 days. Still more preferably, administration provides a concentration of spinosyn of more than about 400 ng/mL and less than about 1500 ng/mL in said mammal’s blood for at least 30 days.
  • administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 6000 ng/mL in said mammal’s blood for at least 365 days. More preferably, administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 2500 ng/mL in said mammal’s blood for at least 365 days. Still more preferably, administration provides a concentration of spinosyn of more than about 300 ng/mL and less than about 2000 ng/mL in said mammal’s blood for at least 365 days. Still more preferably, administration provides a concentration of spinosyn of more than about 400 ng/mL and less than about 1500 ng/mL in said mammal’s blood for at least 365 days.
  • a pool of 40 dogs are to be screened before inclusion in this example by preliminarily infesting them with - 100 unfed adult Ctenocephalides felis in order to produce a pool of dogs that can suitably sustain a reliable infestation rate of approximately 50% of live fleas over a 48-hour period.
  • the dogs with the highest live flea counts are to be randomly allocated to 2 treatment groups (6 dogs per group) based on their pretreatment flea counts from experimental infestations.
  • the first treatment group is to be the control group and the second treatment group to be the test group.
  • the dogs are to be housed individually during the study period and are to be fed a commercial dry dog food ration with ad libitum access to water.
  • Each dog in the test group is to receive by mouth a liquid formulation of spinosyn preferably spinosad.
  • the dosage of 2.5 mg/kg of the dog’s weight is to be administered to the dogs on each of days 0-29 and the dosage of 5 mg/kg of the dog’s weight is to be administered on days 30-50.
  • Dogs in the control group are not to receive spinosyn or any other tick control treatment.
  • Each dog in the test group is to be offered its daily ration (dry food) and the individual doses of liquid formulation are to be administered after the individual dog has eaten at least 25% of its total daily ration. After receiving the dose of spinosyn the dogs are to be allowed to continue eating. This mimics incorporating the spinosyn in feed.
  • Each dog in the test group and the control group is to be experimentally infested with 50 unfed adult ticks (ca. 50% male/50% female) on test days 12, 19, 28, 35, 42, 49 and 56. Comb counts for attached live and moribund adult ticks are to be conducted on days 14, 21, 30, 37, 44, 51 and 58. Note that the dosage is to be increased at day 30 and the final dose is to be given on day 50.
  • Results Percent reduction in attached live and moribund adult tick counts for the test group as compared to the control group is shown in the graph below with spinosad.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Nutrition Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Insects & Arthropods (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Fodder In General (AREA)
  • Feed For Specific Animals (AREA)

Abstract

L'invention concerne un aliment pour animaux administré par voie orale et un procédé de lutte contre les tiques chez un mammifère en ayant besoin par administration orale au mammifère d'une quantité efficace d'une spinosyne pendant une durée efficace pour ainsi amener la quantité de spinosyne dans le sang du mammifère à s'élever et à se maintenir à un niveau thérapeutiquement efficace pour lutter contre les tiques.
EP22768046.9A 2021-03-11 2022-03-11 Aliment et procédés de lutte contre les infestations par les tiques chez un mammifère Pending EP4304605A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159644P 2021-03-11 2021-03-11
PCT/US2022/019870 WO2022192618A1 (fr) 2021-03-11 2022-03-11 Aliment et procédés de lutte contre les infestations par les tiques chez un mammifère

Publications (2)

Publication Number Publication Date
EP4304605A1 true EP4304605A1 (fr) 2024-01-17
EP4304605A4 EP4304605A4 (fr) 2025-01-22

Family

ID=83227122

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22768046.9A Pending EP4304605A4 (fr) 2021-03-11 2022-03-11 Aliment et procédés de lutte contre les infestations par les tiques chez un mammifère

Country Status (10)

Country Link
US (1) US20230413818A1 (fr)
EP (1) EP4304605A4 (fr)
JP (1) JP2024511953A (fr)
KR (1) KR20230161995A (fr)
CN (1) CN117377477A (fr)
AU (1) AU2022234318A1 (fr)
BR (1) BR112023017501A2 (fr)
CA (1) CA3211585A1 (fr)
MX (1) MX2023010379A (fr)
WO (1) WO2022192618A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664237B1 (en) * 1999-08-12 2003-12-16 Eli Lilly And Company Oral treatment of companion animals with ectoparasiticidal spinosyns
WO2005041950A1 (fr) * 2003-11-04 2005-05-12 Akzo Nobel N.V. Preparations ectoparasiticides de spinosynes et de pesticides a base d'azole
UA108200C2 (uk) * 2009-05-08 2015-04-10 Лікарські форми та способи застосування ектопаразитоцидів
AU2011323082B2 (en) * 2010-11-05 2015-06-11 Eli Lilly And Company Methods for inhibiting insect infestations
EP2811998B1 (fr) * 2012-02-06 2018-11-14 Merial, Inc. Compositions parasiticides orales vétérinaires comprenant des agents actives à action systémique et leurs utilisations
WO2014194503A1 (fr) * 2013-06-06 2014-12-11 Eli Lilly And Company Composés parasiticides, procédés et préparations
WO2018183512A1 (fr) * 2017-03-28 2018-10-04 Piedmont Animal Health, Llc Combinaisons d'acaricides et de régulateurs de croissance d'insectes lutter contre les puces sans provoquer de vomissement chez les animaux

Also Published As

Publication number Publication date
JP2024511953A (ja) 2024-03-18
BR112023017501A2 (pt) 2023-12-05
AU2022234318A1 (en) 2023-09-21
US20230413818A1 (en) 2023-12-28
MX2023010379A (es) 2024-01-24
CN117377477A (zh) 2024-01-09
WO2022192618A1 (fr) 2022-09-15
EP4304605A4 (fr) 2025-01-22
KR20230161995A (ko) 2023-11-28
CA3211585A1 (fr) 2022-09-15

Similar Documents

Publication Publication Date Title
JP5427217B2 (ja) コンパニオン動物における害虫の経口処置
JP6952678B2 (ja) ディロフィラリア症の拡大を抑制するためのネオニコチノイドとピレスロイドとの組合せ
US20230413818A1 (en) Feed and methods for controlling tick infestations in a mammal
WO2018183512A1 (fr) Combinaisons d'acaricides et de régulateurs de croissance d'insectes lutter contre les puces sans provoquer de vomissement chez les animaux
JP2015523388A (ja) 外部寄生虫撲滅薬スピノサドを用いてネコを治療するための単回用量経口製剤および方法
US20240138442A1 (en) Oral feline feed and methods for controlling flea infestations in a feline
US20230414644A1 (en) Oral canine feed and methods for controlling flea infestations in a canine
US20230413819A1 (en) Methods for controlling flea and tick infestations in a mammal
EP2053917B1 (fr) Composition à activité antiparasitaire améliorée
White Update in feline dermatology: newly described treatments.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240516

A4 Supplementary search report drawn up and despatched

Effective date: 20250102

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 33/14 20060101ALI20241218BHEP

Ipc: A61K 31/35 20060101ALI20241218BHEP

Ipc: A01P 7/02 20060101ALI20241218BHEP

Ipc: A01N 43/22 20060101ALI20241218BHEP

Ipc: A61K 9/00 20060101ALI20241218BHEP

Ipc: A61K 45/06 20060101ALI20241218BHEP

Ipc: A61K 31/7048 20060101AFI20241218BHEP